Emerging therapies to prevent skeletal morbidity in men with prostate cancer.
about
Contemporary Management of Prostate CancerComparative efficacy, tolerability, and survival outcomes of various radiopharmaceuticals in castration-resistant prostate cancer with bone metastasis: a meta-analysis of randomized controlled trialsRecent progress in pharmaceutical therapies for castration-resistant prostate cancerRadium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease.Optimizing bone health and minimizing skeletal morbidity in men with prostate cancerBioengineered implantable scaffolds as a tool to study stromal-derived factors in metastatic cancer models.Proteomic analysis of zoledronic-acid resistant prostate cancer cells unveils novel pathways characterizing an invasive phenotype.Future perspectives of prostate cancer therapy.Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer.Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells.Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancerA dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.Optimal bone health management strategies in patients with prostate cancerAdverse effects of androgen deprivation therapy for prostate cancer: prevention and managementRadiation safety considerations for the use of ²²³RaCl₂ DE in men with castration-resistant prostate cancerTargeted α-particle therapy of bone metastases in prostate cancerMacrophage cathepsin K promotes prostate tumor progression in bone.Drugs that offer a survival advantage for men with bone metastases resulting from castration-resistant prostate cancer: new and emerging treatment options.Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: the Australian perspective.Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases.AST-induced bone loss in men with prostate cancer: exercise as a potential countermeasure.Overview of the latest treatments for castration-resistant prostate cancer.Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-naïve prostate cancer.Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases.Circulating tumour cells-monitoring treatment response in prostate cancer.'First, do no harm': managing the metabolic impacts of androgen deprivation in men with advanced prostate cancer.Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials.Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib.Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the mevalonate pathway in disease progression?Modulation of cabozantinib efficacy by the prostate tumor microenvironment.Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer.Q57133506
P2860
Q26767456-2A43B9CF-2CC2-4C50-938B-04C6D15CF11CQ26785658-CB1A8F71-D6F3-4D15-BC13-7291327A1CF0Q27022567-F29FEA5C-07D5-4F20-93B4-510753FD77CBQ33405335-459C701D-F461-44A0-9F60-827572EB0545Q34023510-81E3393D-FFB4-448D-96EC-1BD21818AF31Q34713778-ED98D7AF-E09B-4847-9AB4-0998F35351CDQ35497211-9227AABA-F8FF-40DF-9507-C7AB821B632BQ36076453-386B9E72-05D3-430B-A083-F077407D5A72Q36840731-58E86FE0-D563-4AC2-B500-5FF878C33775Q36907149-529CE37D-14F9-47DA-8A12-8A695BA4DDDAQ36931715-84C0C5D6-2CD9-4A12-89AF-FB287841E4BEQ36934749-EDAE3B2B-8A1D-453A-A90E-4F9F20E5528CQ37080734-223575F3-CF2A-4203-89FE-4337958A9E4FQ37105407-30F50F65-541A-4DE0-89D9-2E1F3364629AQ37168396-AF25E699-6163-4473-A51E-0C503FFB869FQ37417656-19815B12-2ED3-4CD1-AAAE-67820CFF7604Q37554550-53977B35-484C-4418-97CD-91FBAD58DCC1Q37641292-666D5ED6-C476-41A3-90FB-AD6350BB7E73Q37673201-6AFF3D60-1E11-4CE2-A7CC-A51C686644E0Q37988590-7A00CB3F-93E6-486B-9006-59E16DDF13B4Q38004275-F0E14A84-BF7F-4579-85A7-561F9803A9EBQ38021668-5EA32FD9-F973-449E-9EBE-BD83B8C58C90Q38116754-231DF080-9E6D-4942-A7F1-604D5A0E4C21Q38172209-380B5C99-795A-4E46-ABDF-0925E08F2F44Q38194528-0FD184F5-FD8B-4A93-AB2C-C83C9ED80A4FQ38211361-A99820A4-B06A-49F8-9151-974C69F3DCDAQ38366829-084288BE-EDA9-4968-AC1F-8739C486C534Q41319701-4045CDC2-C15A-4B01-A0B4-BB6A9B17CA6EQ42231093-4F10E552-EEF2-490A-B22A-87C965AE4550Q44538922-F0386982-49CA-467C-8819-09E3BDF3E269Q46493299-83319D79-14A8-4037-A89A-A8864FE04102Q53786874-CEA016AC-433A-4501-AAA4-E1A5A83A41E9Q57133506-8CAE41DD-9616-4475-A3CC-6078C2B9B4BE
P2860
Emerging therapies to prevent skeletal morbidity in men with prostate cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Emerging therapies to prevent skeletal morbidity in men with prostate cancer.
@en
type
label
Emerging therapies to prevent skeletal morbidity in men with prostate cancer.
@en
prefLabel
Emerging therapies to prevent skeletal morbidity in men with prostate cancer.
@en
P2093
P2860
P356
P1476
Emerging therapies to prevent skeletal morbidity in men with prostate cancer.
@en
P2093
Matthew R Smith
Philip J Saylor
Richard J Lee
P2860
P304
P356
10.1200/JCO.2010.34.4994
P407
P577
2011-08-22T00:00:00Z